Anika Therapeutics (ANIK) Consolidated Net Income (2016 - 2025)
Historic Consolidated Net Income for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $846000.0.
- Anika Therapeutics' Consolidated Net Income rose 10301.36% to $846000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.8 million, marking a year-over-year decrease of 5650.33%. This contributed to the annual value of -$47.6 million for FY2024, which is 3997.45% up from last year.
- Per Anika Therapeutics' latest filing, its Consolidated Net Income stood at $846000.0 for Q3 2025, which was up 10301.36% from $677000.0 recorded in Q2 2025.
- In the past 5 years, Anika Therapeutics' Consolidated Net Income registered a high of $16.2 million during Q4 2023, and its lowest value of -$28.1 million during Q3 2024.
- Its 5-year average for Consolidated Net Income is -$2.3 million, with a median of -$2.6 million in 2024.
- Over the last 5 years, Anika Therapeutics' Consolidated Net Income had its largest YoY gain of 41137.91% in 2022, and its largest YoY loss of 85398.55% in 2022.
- Anika Therapeutics' Consolidated Net Income (Quarter) stood at -$3.2 million in 2021, then surged by 411.38% to $10.1 million in 2022, then surged by 60.71% to $16.2 million in 2023, then tumbled by 219.74% to -$19.4 million in 2024, then surged by 104.37% to $846000.0 in 2025.
- Its last three reported values are $846000.0 in Q3 2025, $677000.0 for Q2 2025, and -$915000.0 during Q1 2025.